A lower priced version of this book is available
Save £2.99 (20%) by choosing the Kindle Edition.
£9.49
Kindle price
£12.48
Paperback price

Save <span class="a-color-price">£2.99 (20%)</span> by choosing the Kindle Edition. Read now with the free Kindle app
Available on iOS, Android, Mac & PC.
  • RRP: £14.99
  • You Save: £2.51 (17%)
FREE Delivery in the UK.
In stock.
Dispatched from and sold by Amazon. Gift-wrap available.
Juvenescence: Investing i... has been added to your Basket
+ £2.80 delivery
Used: Very Good | Details
Condition: Used: Very Good
Comment: Expedited shipping available on this book. The book has been read, but is in excellent condition. Pages are intact and not marred by notes or highlighting. The spine remains undamaged.
Have one to sell?
Flip to back Flip to front
Listen Playing... Paused   You're listening to a sample of the Audible audio edition.
Learn more
See this image

Juvenescence: Investing in the Age of Longevity Paperback – 25 Sep 2017

4.1 out of 5 stars 19 customer reviews

See all 2 formats and editions Hide other formats and editions
Amazon Price
New from Used from
Kindle Edition
Paperback
£12.48
£8.95 £7.98
Note: This item is eligible for click and collect. Details
Pick up your parcel at a time and place that suits you.
  • Choose from over 13,000 locations across the UK
  • Prime members get unlimited deliveries at no additional cost
How to order to an Amazon Pickup Location?
  1. Find your preferred location and add it to your address book
  2. Dispatch to this address when you check out
Learn more
click to open popover


Frequently bought together

  • Juvenescence: Investing in the Age of Longevity
  • +
  • Cracking the Code: Understand and Profit from the Biotech Revolution That Will Transform Our Lives and Generate Fortunes
Total price: £29.47
Buy the selected items together

Enter your mobile number or email address below and we'll send you a link to download the free Kindle App. Then you can start reading Kindle books on your smartphone, tablet, or computer - no Kindle device required.

  • Apple
  • Android
  • Windows Phone

To get the free app, enter your mobile phone number.



Only on Amazon: One product for every need Only on Amazon: New Releases


Product details

  • Paperback: 250 pages
  • Publisher: Fruitful Publications (25 Sept. 2017)
  • Language: English
  • ISBN-10: 0993047815
  • ISBN-13: 978-0993047817
  • Product Dimensions: 14.7 x 2.5 x 20.8 cm
  • Average Customer Review: 4.1 out of 5 stars 19 customer reviews
  • Amazon Bestsellers Rank: 46,022 in Books (See Top 100 in Books)
  • Would you like to tell us about a lower price?
    If you are a seller for this product, would you like to suggest updates through seller support?

Product description

Review

"Jim Mellon s vision may be optimistic but it s certainly not fanciful. He came to the conclusions he draws in his new book, Juvenescence, after he immersed himself in the subject of longevity research for well over a year. This included a 7,000-mile road trip around America, visiting scientists at the cutting edge of this research...Mellon s book offers three possible portfolios and includes a thorough analysis of the companies recommended." ----Julie Blackburn, The Telegraph

About the Author

Jim Mellon is an investor with an interest in several industries. After studying PPE at Oxford, Jim worked in Asia and in the US for two fund management companies, GT Management and Thornton & Co, before establishing his own business in 1991. This business is now known by two names - Charlemagne Capital, recently acquired, and Regent Pacific Group, listed in Hong Kong. Jim's private investment company, The Burnbrae Group, is a substantial landlord in Germany and the Isle of Man, and owns the group Sleepwell Hotels. Jim is chairman and major shareholder of Manx Financial Group, Port Erin Biopharma Invesments and SalvaRx Group. He is also a director of Condor Gold, Fast Forward Innovations, Portage Biotech and West African Minerals Corporation, all publicly listed companies. A new venture, Juvenescence will provide investors with the opportunity to invest alongside his partners in longevity, is expected to be launched sometime in 2017.Amongst his many successes, Jim is well know for notching up one of the AIM market's biggest successes with the sale of Uramin to Areva, the French nuclear giant.Al Chalabi is an entrepreneur and business advisor with a diverse professional background. He grew up in the UK and studied Aeronautical Engineering at the University of Southampton. Al started his career in Canada, working as an engineer in process automation systems. After his MBA, he worked as a management consultant, specialising in technology, strategy and operations, based out of Hong Kong. Since 2008, Al has been running CASP-R, a firm he founded to provide independent research and advisory services to investors and corporations, with a focus on real estate and technology. He is active in various Hong Kong-based angel investor groups that provide seed and growth funding to Asian-based tech and healthcare companies.


19 customer reviews

4.1 out of 5 stars

Review this product

Share your thoughts with other customers

Read reviews that mention

Showing 1-8 of 19 reviews

9 October 2017
Format: PaperbackVerified Purchase
4 people found this helpful
Comment Report abuse
9 July 2018
Format: PaperbackVerified Purchase
13 January 2018
Format: Kindle EditionVerified Purchase
2 people found this helpful
Comment Report abuse
14 August 2018
Format: Kindle EditionVerified Purchase
21 January 2018
Format: PaperbackVerified Purchase
One person found this helpful
Comment Report abuse
30 October 2017
Format: PaperbackVerified Purchase
20 October 2017
Format: Kindle EditionVerified Purchase
8 people found this helpful
Comment Report abuse
2 December 2017
Format: PaperbackVerified Purchase

Would you like to see more reviews about this item?

Pages with related products. See and discover other items: investing books

Where's My Stuff?

Delivery and Returns

Need Help?